Physician profile
Lekeshia Smith
NPI 1366074569
$3,108.43
in general payments reported to CMS, 2019-2025
13 companies · $517 in 2025
The $517 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $450 · 2023: $524 · 2024: $770 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,282.30 | 2021-2024 | Farxiga, Breztri, Lokelma |
| Amgen INC. | $351.28 | 2021-2022 | |
| Glaxosmithkline, LLC. | $288.70 | 2022-2025 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $247.10 | 2023-2024 | |
| Novo Nordisk INC | $244.73 | 2025 | Ozempic, Wegovy |
| Travere Therapeutics, INC. | $132.84 | 2024 | |
| Vifor Pharma, INC. | $131.54 | 2025 | Veltassa |
| Calliditas Therapeutics US INC. | $122.78 | 2022 | |
| Mallinckrodt Hospital Products INC. | $121.82 | 2025 | Terlivaz |
| Fresenius USA Marketing, INC. | $121.17 | 2023 | Korsuva |
| Ardelyx, INC. | $26.03 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $22.56 | 2023 | Gattex |
| Akebia Therapeutics INC | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lekeshia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.